Combined Treatment With Leuprolide Acetate and Burosumab in X-linked Hypophosphatemia and Precocious Puberty: A Therapeutic Response
In the described XLH patient with CPP, the combined use of gonadotropin-releasing hormone analogs and burosumab was a safe strategy to stabilize pubertal progression and bone age, minimize anthropometric loss, and avoid exacerbating bone deformities.
Authors
- Guido de Paula Colares Neto (ORCID: https://orcid.org/0000-0003-3355-0386)
- Vânia de Fátima Tonetto Fernandes (ORCID: https://orcid.org/0000-0001-8507-5236)
- G Penna (ORCID: https://orcid.org/0000-0002-7396-5538)
- Patricia Salmona (ORCID: https://orcid.org/0000-0002-5689-9049)
- Carolina Costa Figueiredo (ORCID: https://orcid.org/0000-0002-1781-3214)
- Nara Michelle de Araújo Evangelista (ORCID: https://orcid.org/0000-0003-2323-3563)
Institutions
- Centro Universitário São Camilo (BR)
- Hospital Vargas (VE)
Publication Details
- Journal
- AACE Clinical Case Reports
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1016/j.aace.2024.09.004
- Citations
- 1
- Primary Topic
- Dermatological and Skeletal Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.55